Media stories about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galectin Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.6260599627224 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Several equities research analysts have recently commented on GALT shares. ValuEngine lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, May 30th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $2.25.

Shares of Galectin Therapeutics (NASDAQ GALT) traded up 5.81% during midday trading on Monday, hitting $1.82. The stock had a trading volume of 349,520 shares. The firm has a 50 day moving average of $2.22 and a 200-day moving average of $2.21. The company’s market cap is $63.10 million. Galectin Therapeutics has a one year low of $0.49 and a one year high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.01. During the same quarter last year, the business posted ($0.20) EPS. On average, analysts forecast that Galectin Therapeutics will post ($0.56) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Galectin Therapeutics (NASDAQ:GALT) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.